

Disclosure Purpose: 21-16298

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
American Academy of Pediatrics	Grant / Contract	Self
<i>Recipient Name:</i> Elizabeth Barnett <i>Grant / Contract Description:</i> Associate Editor, Red Book <i>Additional Information:</i>		<i>Recipient Type:</i> Individual <i>Grant / Contract Purpose:</i> Other - editing
Pfizer Inc.	Grant / Contract	Self
<i>Recipient Name:</i> Boston Medical Center <i>Grant / Contract Description:</i> RSV vaccine for pregnant women study PCV20 vaccine study COVID vaccine studies		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research <i>Additional Information:</i>

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Safety and Immunogenicity of BNT162b2 COVID-19 Vaccine in 5-11 Year Olds
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16298

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
Pfizer, Inc	Employment	Self
<i>Title:</i> Associate Director <i>Additional Information:</i>		<i>Position Description:</i> Head of OPA and SARS-CoV-2 Neutralization Assays

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Safety and Immunogenicity of BNT162b2 COVID-19 Vaccine in 5-11 Year Olds
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16298

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Pfizer	Employment	Self
<i>Title:</i> Executive Director <i>Additional Information:</i>		<i>Position Description:</i> Vaccine Researcher
Pfizer	Stock	Self
<i>Additional Information:</i>		
Pfizer	Stock Option	Self
<i>Additional Information:</i>		

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Safety and Immunogenicity of BNT162b2 COVID-19 Vaccine in 5-11 Year Olds
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16298

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Pfizer Limited	Employment	Self
<i>Title:</i> Clinical Scientist		<i>Position Description:</i> Responsible for bringing together clinical, scientific and technical disciplines to ensure high quality protocol development, study execution and data interpretation.
<i>Additional Information:</i>		

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Safety, Immunogenicity and Efficacy of the BNT162b2 COVID-19 Vaccine in 5-11 Year Olds
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-16298

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
Pfizer International LLC	Other	Self
<i>Category:</i> Other <i>Additional Information:</i> Payments made to my employer, SUNY Upstate Medical University on my behalf for clinical trial activities		<i>Description:</i> Site investigator for clinical trial

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
"Safety, Immunogenicity and Efficacy of the BNT162b2 COVID-19 Vaccine in 5-11 Year Olds,"
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16298

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Pfizer	Employment	Self
<i>Title:</i> Vice President and Chief Scientific Officer Viral and RNA Vaccines <i>Additional Information:</i>		<i>Position Description:</i>
Pfizer	Stock Option	Self
<i>Additional Information:</i>		

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Safety and Immunogenicity of BNT162b2 COVID-19 Vaccine in 5-11 Year Olds
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16298

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Pfizer	Grant / Contract	Self

Recipient Name: Cincinnati Children's Hospital Medical Center
Grant / Contract Description: Clinical Trial grant for COVID-19 vaccines
Additional Information:

Recipient Type: Institution
Grant / Contract Purpose: Research

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Safety and Immunogenicity of BNT162b2 COVID-19 Vaccine in 5-11 Year Olds
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-16298

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Pfizer	Employment	Self
<i>Title:</i> Senior Vice President		<i>Position Description:</i> Vaccine Clinical Research and Development Worldwide Research Development and Medical
<i>Additional Information:</i>		
Pfizer	Stock	Self
<i>Additional Information:</i>		
Pfizer	Stock Option	Self
<i>Additional Information:</i>		

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Safety and Immunogenicity of BNT162b2 COVID-19 Vaccine in 5-11 Year Olds
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-16298

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
Pfizer	Employment	Self
<i>Title:</i> VP Vaccine Clinical Research and Development <i>Additional Information:</i>		<i>Position Description:</i>

Additional Questions:

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Safety and Immunogenicity of the BNT162b2 COVID-19 Vaccine in 5-11 Year Olds

3. **Are you the corresponding author?**

Yes.

a. **Please list the other authors' names here.**

1. Emmanuel B. Walter, MD (Duke Human Vaccine Institute, Durham, NC, USA)* 2. Kawsar R. Talaat, MD (Johns Hopkins University, Baltimore, MD, USA)* 3. Charu Sabharwal, MD, MPH (Vaccine Research and Development, Pfizer Inc, Pearl River, NY, USA) 4. Alejandra Gurtman, MD (Vaccine Research and Development, Pfizer Inc, Pearl River, NY, USA) 5. Stephen Lockhart, DM (Vaccine Research and Development, Pfizer Ltd, Hurley, UK) 6. Grant C. Paulsen, MD (Department of Pediatrics, University of Cincinnati College of Medicine and Division of Pediatric Infectious Diseases, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA) 7. Elizabeth D. Barnett, MD (Boston Medical Center, Boston University School of Medicine, Boston, MA, USA) 8. Flor M. Munoz, MD (Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA) 9. Yvonne Maldonado, MD (Stanford University School of Medicine, Palo Alto, CA, USA) 10. Barbara A. Pahud, MD, MPH (Children's Mercy Hospital, Kansas City, MO, USA)† 11. Joseph B. Domachowske, MD (SUNY Upstate Medical University, Syracuse, NY, USA) 12. Uzma N. Sarwar, MD (Vaccine Research and Development, Pfizer Inc, Pearl River, NY, USA) 13. Nicholas Kitchin, MD (Vaccine Research and Development, Pfizer Ltd, Hurley, UK) 14. Luke Cunliffe, BSc (Vaccine Research and Development, Pfizer Ltd, Hurley, UK) 15. Pablo Rojo, MD (Hospital Universitario 12 de Octubre, Madrid, Spain) 16. Ernest Kuchar, MD, PhD (Medical University of Warsaw, Warsaw, Poland) 17. Mika Rämetsä, MD, PhD (Tampere University Vaccine Research Center, Tampere, Finland, and PEDEGO Research Unit, University of Oulu, Oulu, Finland) 18. Iona Munjal, MD (Vaccine Research and Development, Pfizer Inc, Pearl River, NY, USA) 19. John L. Perez, MD, MBA, MA (Vaccine Research and Development, Pfizer Inc, Collegeville, PA, USA) 20. Robert W. Frenck, Jr., MD (Department of Pediatrics, University of Cincinnati College of Medicine and Division of Pediatric Infectious Diseases, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA)

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16298

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Pfizer	Employment	Self
<i>Title:</i> SVP and Head of vaccine R&D <i>Additional Information:</i>		<i>Position Description:</i> head of vaccine R&D
Pfizer	Stock	Self
<i>Additional Information:</i> as a Pfizer employee i hold PFE stock and stock options		

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Safety and Immunogenicity of BNT162b2 COVID-19 Vaccine in 5-11 Year Olds
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-16298

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
Pfizer	Employment	Self
<i>Title:</i> Executive Director <i>Additional Information:</i> Full time employee		<i>Position Description:</i> Vaccine Clinical Research and Development
Pfizer	Stock	Self
<i>Additional Information:</i>		
Pfizer	Stock Option	Self
<i>Additional Information:</i>		

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Safety and Immunogenicity of BNT162b2 COVID-19 Vaccine in 5-11 Year Olds
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16298

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
Pfizer	Employment	Self
<i>Title:</i> Executive Director <i>Additional Information:</i>		<i>Position Description:</i> Head of Statistics and Modeling, Vaccine Clinical Research and Development
Pfizer	Stock	Self
<i>Additional Information:</i>		

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Safety and Immunogenicity of BNT162b2 COVID-19 Vaccine in 5-11 Year Olds
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16298

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Safety and Immunogenicity of BNT162b2 COVID-19 Vaccine in 5-11-Year-Olds
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-16298

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
BioNTech SE	Employment	Self
<i>Title:</i> Vice President Clinical Research <i>Additional Information:</i>		<i>Position Description:</i>

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Safety and Immunogenicity of BNT162b2 COVID-19 Vaccine in 5-11 Year Olds
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-16298

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
Pfizer	Employment	Self
<i>Title:</i> Vice President <i>Additional Information:</i>		<i>Position Description:</i> Clinical Research Head Vaccines Europe and Asia Pacific
Pfizer	Stock	Self
<i>Additional Information:</i>		
Pfizer	Stock Option	Self
<i>Additional Information:</i>		

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
No.
- What is the manuscript title?
Safety and Immunogenicity of BNT162b2 COVID-19 Vaccine in 5-11 Year Olds
- Are you the corresponding author?
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16298

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Pfizer	Employment	Self
<i>Title:</i> Senior Manager, Biostatistics <i>Additional Information:</i>		<i>Position Description:</i> Clinical trial statistician
Pfizer	Stock	Self
<i>Additional Information:</i>		

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Safety and Immunogenicity of BNT162b2 COVID-19 Vaccine in 5-11 Year Olds
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-16298

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Pfizer Inc.	Grant / Contract	Self
<i>Recipient Name:</i> Stanford University School of Medicine <i>Grant / Contract Description:</i> Pfizer Maternal RSV Vaccine Clinical Trial <i>Additional Information:</i> Stanford Site Principal Investigator for this vaccine trial		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Pfizer Inc.	Grant / Contract	Self
<i>Recipient Name:</i> Stanford University School of Medicine <i>Grant / Contract Description:</i> Pfizer Pediatric COVID-19 Vaccine Clinical Trials <i>Additional Information:</i> Stanford Site Principal Investigator for Pfizer Pediatric Vaccine Clinical Trials		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Pfizer Inc.	Data And Safety Monitoring	Self
<i>Category:</i> Data And Safety Monitoring <i>Additional Information:</i>		<i>Description:</i> Member, DSMB, Pfizer Meningococcal Vaccines Clinical Trials

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.
- What is the manuscript title?**

Safety, Immunogenicity and Efficacy of the BNT162b2 COVID-19 Vaccine in 5-11 Year Olds
- Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16298

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Pfizer Inc.	Employment	Self
<i>Title:</i> Director, Vaccine Clinical Research and Development		<i>Position Description:</i> Medical Monitor overseeing ongoing vaccine clinical trials
<i>Additional Information:</i>		
Pfizer Inc.	Stock	Self
<i>Additional Information:</i>		

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Safety and Immunogenicity of BNT162b2 COVID-19 Vaccine in 5-11 Year Olds
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-16298

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
Moderna	Data And Safety Monitoring	Self
<i>Category:</i> Data And Safety Monitoring <i>Additional Information:</i>		<i>Description:</i> Various vaccines
Pfizer Inc.	Data And Safety Monitoring	Self
<i>Category:</i> Data And Safety Monitoring <i>Additional Information:</i>		<i>Description:</i> RSV vaccines

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Safety and Immunogenicity of BNT162b2 COVID-19 Vaccine in 5-11 Year Olds
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16298

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Merck	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> Presented and participated at forum		<i>Description:</i> service on US Vaccine Confidence Expert Input Forum
Pfizer	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> limited time consultant for topic specific story		<i>Description:</i> Consultant for Trumenba Science Story
Pfizer	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> Time limited consultant for topic specific activity		<i>Description:</i> Consultant for Pediatric Pneumococcal PEGASUS
Pfizer	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> Consultant for one time meeting on topic specific discussion		<i>Description:</i> Consultant for Virtual Discussion about future pediatric PCV recommendations in the US
Pfizer	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> Limited time Consultant for topic specific broadcast		<i>Description:</i> Consultant for Spring 2021 Trumenba Premiere Broadcast
SANOFI PASTEUR INC.	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> Hotel and flight was booked by the funder		<i>Description:</i> Presented at the International Forum Voices for Vaccination on 8/29/19 in Mexico City, MX
SANOFI PASTEUR INC.	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> Served as speaker to healthcare professionals on topics specific to vaccines & vaccine hesitancy		<i>Description:</i> provided presentations as requested
SANOFI PASTEUR INC.	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> limited time scientific/vaccine consultant for the production of educational videos to support HCPs in managing vaccine hesitancy		<i>Description:</i> Scientific consultant & Medical Expert

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
No.
- What is the manuscript title?
Safety and Immunogenicity of BNT162b2 COVID-19 Vaccine in 5-11 Year Olds
- Are you the corresponding author?
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16298

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
PFIZER CANADA INC	Grant / Contract	Self
<i>Recipient Name:</i> Grant Paulsen <i>Grant / Contract Description:</i> Grant/Contract support from Pfizer to conduct a clinical vaccine trial. <i>Additional Information:</i> Support is ~10% of my time/salary as the Site PI for the trial.		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Safety and Immunogenicity of BNT162b2 COVID-19 Vaccine in 5-11 Year Olds
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16298

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Pfizer	Employment	Self
<i>Title:</i> Vice President Vaccine Clinical Research & Development		<i>Position Description:</i>
<i>Additional Information:</i>		

Intellectual Property

Type	Is Licensed	Interest Held By
Patent - Meningococcal Pentavalent vaccine	No	Self
<i>Description:</i> Meningococcal Pentavalent vaccine	<i>Patent Number:</i> 10,813,989 B2	<i>Patent Holder:</i> Current Institution
<i>Patent Status:</i> Issued	<i>Additional Information:</i>	
<i>Filing Jurisdiction:</i> USA		
<i>Licensees:</i>		

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
No.
- What is the manuscript title?
Safety and Immunogenicity of BNT162b2 COVID-19 Vaccine in 5-11 Year Olds
- Are you the corresponding author?
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16298

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
GlaxoSmithKline	Other	Self
<p>Category: Other Description: National coordinator and/or PI for clinical trials Additional Information: National coordinator and/or PI for several clinical vaccine trials sponsored by GSK. However, I am employed by the Tampere University which has made the contract with the sponsor whereas I have not personally received any direct compensation from GSK.</p>		
Janssen Biotech	Other	Self
<p>Category: Other Description: National coordinator and/or PI for clinical vaccine trials Additional Information: National coordinator and/or PI for several clinical vaccine trials sponsored by Janssen. However, I am employed by the Tampere University which has made the contract with the sponsor whereas I have not personally received any direct compensation from Janssen.</p>		
MedImmune	Other	Self
<p>Category: Other Description: National coordinator and/or PI for clinical vaccine trials Additional Information: National coordinator and/or PI for several clinical vaccine trials sponsored by MedImmune. However, I am employed by the Tampere University which has made the contract with the sponsor whereas I have not personally received any direct compensation from MedImmune.</p>		
Merck Sharp and Dohme	Other	Self
<p>Category: Other Description: National coordinator and/or PI for clinical vaccine trials Additional Information: National coordinator and/or PI for several clinical vaccine trials sponsored by MSD. However, I am employed by the Tampere University which has made the contract with the sponsor whereas I have not personally received any direct compensation from MSD.</p>		
Pfizer Inc.	Other	Self
<p>Category: Other Description: Clinical Trial, National coordinator Additional Information: National coordinator and/or PI for several clinical vaccine trials sponsored by Pfizer. However, I am employed by the Tampere University which has made the contract with the sponsor whereas I have not personally received any direct compensation from Pfizer.</p>		
SANOFI PASTEUR INC.	Other	Self
<p>Category: Other Description: National coordinator and/or PI for clinical trials Additional Information: National coordinator and/or PI for several clinical vaccine trials sponsored by SanofiPasteur. However, I am employed by the Tampere University which has made the contract with the sponsor whereas I have not personally received any direct compensation from SanofiPasteur.</p>		

Additional Questions:

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

Yes.

- a. Please describe those relationships.

I have been the national coordinator in Finland for this study which was sponsored by Pfizer. However, I am employed by the Tampere University which has made the contract with the sponsor whereas I have not personally received any direct compensation from Pfizer.

2. What is the manuscript title?
Safety and Immunogenicity of BNT162b2 COVID-19 Vaccine in 5-11 Year Olds
3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16298

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Safety and Immunogenicity of BNT162b2 COVID-19 Vaccine in 5-11 Year Olds
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-16298

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Pfizer	Employment	Self
<i>Title:</i> Director		<i>Position Description:</i> Medical Monitor within Vaccine Clinical Research and Development
<i>Additional Information:</i>		

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Safety and Immunogenicity of BNT162b2 COVID-19 Vaccine in 5-11 Year Olds
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-16298

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
biontech	Fiduciary Officer	Self
<i>Official Title:</i> Chief Executive Officer, Co-Founder		<i>Position Description:</i> Member of the Board
<i>Additional Information:</i>		
biontech	Stock	Self
<i>Additional Information:</i>		
biontech	Stock Option	Self
<i>Additional Information:</i>		

Intellectual Property

Type	Is Licensed	Interest Held By				
Patent - 3 UTR Sequences for stabilisation of mRNA	Yes	Self				
<i>Description:</i> 3 UTR Sequences for stabilisation of mRNA		<i>Patent Number:</i> EPPCT/EP2015/073180, US 20190071682				
<i>Patent Status:</i> Pending		<i>Patent Holder:</i> Previous Institution				
<i>Filing Jurisdiction:</i> USA		<i>Additional Information:</i> I am co-inventors on various patents on RNA Technologies, both pending and granted, which have been filed over a period of 10+ years, some of which are licensed to third parties. Jurisdictions ae Broad including US, EU, Asia.				
<i>Licensees:</i>						
<table border="1"> <thead> <tr> <th>Licensee</th> <th>Title</th> <th>Date</th> </tr> </thead> <tbody> <tr> <td>biontech</td> <td></td> <td></td> </tr> </tbody> </table>	Licensee		Title	Date	biontech	
Licensee	Title	Date				
biontech						

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
No.
- What is the manuscript title?
Evaluation of the BNT162b2 COVID-19 Vaccine in 5-11 Year Olds
- Are you the corresponding author?
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16298

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Pfizer Inc.	Employment	Self
<i>Title:</i> Associate Director <i>Additional Information:</i>		<i>Position Description:</i> Medical Monitor

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Safety and Immunogenicity of BNT162b2 COVID-19 Vaccine in 5-11 Year Olds
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-16298

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
Pfizer Inc.	Grant / Contract	Other - Children's Hospital Colorado and University of Colorado School of Medicine
<i>Recipient Name:</i> Eric Simoes <i>Grant / Contract Description:</i> Grants to conduct trials C4591007, C4591015, C3571002, C3671003, and C3671008,		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research <i>Additional Information:</i>
Regeneron Pharmaceuticals, Inc.	Grant / Contract	Other - University of Colorado School of Medicine and Samshoma Medical Research Inc
<i>Recipient Name:</i> Eric Simoes <i>Grant / Contract Description:</i> R10933-10987-COV-2069 and 0000-COV-CES-2053 <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
No.
- What is the manuscript title?
Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age
- Are you the corresponding author?
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16298

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Pfizer	Employment	Self
<i>Title:</i> Director, Viral Vaccines <i>Additional Information:</i>		<i>Position Description:</i> vaccine research and development
Pfizer	Stock	Self
<i>Additional Information:</i>		

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Safety and Immunogenicity of BNT162b2 COVID-19 Vaccine in 5-11 Year Olds
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-16298

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
Pfizer Inc.	Grant / Contract	Self
<i>Recipient Name:</i> Johns Hopkins University <i>Grant / Contract Description:</i> To conduct 3 clinical trials of the Pfizer-BioNTech vaccine in adults and children. I am the PI.		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research <i>Additional Information:</i>
SANOFI PASTEUR INC.	Grant / Contract	Self
<i>Recipient Name:</i> Johns Hopkins University <i>Grant / Contract Description:</i> To conduct a yellow fever vaccine trial; I am the PI of the trial. <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
No.
- What is the manuscript title?
Safety and Immunogenicity of BNT162b2 COVID-19 Vaccine in 5-11 Year olds
- Are you the corresponding author?
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-16298

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
biontech	Employment	Self
<i>Title:</i> Chief Medical Officer <i>Additional Information:</i> also spouse is board member and CEO of Company since 2008		<i>Position Description:</i> Board member, CO-founder
biontech	Fiduciary Officer	Self
<i>Official Title:</i> Chief Medical Officer <i>Additional Information:</i> also spouse is co-founder and board member (Chief Executive Officer) of Biontech		<i>Position Description:</i> board member, co-founder
biontech	Fiduciary Officer	Spouse/Partner
<i>Official Title:</i> CEO <i>Additional Information:</i>		<i>Position Description:</i>
biontech	Stock	Spouse/Partner
<i>Additional Information:</i> founder, shareholder		
biontech	Stock Option	Self
<i>Additional Information:</i> self and spouse have stock Options. spouse has stock		

Intellectual Property

Type	Is Licensed	Interest Held By						
Patent - Modifications of RNA leading to increased transc ...	Yes	Self						
<i>Description:</i> Modifications of RNA leading to increased transcript stability and translational efficiency <i>Patent Status:</i> Pending <i>Filing Jurisdiction:</i> USA <i>Licensees:</i>		<i>Patent Number:</i> EP1934345B9, DE102005046490.4 <i>Patent Holder:</i> Current Institution <i>Additional Information:</i> self and spouse are co-inventors on various patents on RNA Tech						
<table border="1"> <thead> <tr> <th>Licensee</th> <th>Title</th> <th>Date</th> </tr> </thead> <tbody> <tr> <td>biontech</td> <td></td> <td></td> </tr> </tbody> </table>	Licensee	Title	Date	biontech				
Licensee	Title	Date						
biontech								

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
No.
- What is the manuscript title?
Safety and Immunogenicity of BNT162b2 COVID-19 Vaccine in 5011 Year Old
- Are you the corresponding author?
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16298

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Moderna	Grant / Contract	Self
<i>Recipient Name:</i> Duke University <i>Grant / Contract Description:</i> Conduct of Clinical Trial <i>Additional Information:</i> Co-investigator for Clinical trial		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Pfizer	Grant / Contract	Self
<i>Recipient Name:</i> Duke University <i>Grant / Contract Description:</i> Conduct of Pfizer/BioNTech COVID-19 vaccine studies <i>Additional Information:</i> Principal investigator for clinical trial		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Vaxcyte	Other	Self
<i>Category:</i> Other <i>Additional Information:</i> No financial compensation as of this time		<i>Description:</i> Scientific Advisory Board

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Safety and Immunogenicity of BNT162b2 COVID-19 Vaccine in 5-11 Year Olds
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-16298

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Pfizer	Employment	Self
<i>Title:</i> Sr. Director, Vaccine Statistics <i>Additional Information:</i>		<i>Position Description:</i> Design, conduct, and analysis of vaccine clinical trials

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Safety and Immunogenicity of BNT162b2 COVID-19 Vaccine in 5-11 Year Olds
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

